Diagnostic Assay

Biopeptides, Corp. is a small research and development biotechnology company established in 2002. Dr. Dattwyler, founder, CEO, and president, has served on FDA advisory panels. In his previous company, Brook Biotechnologies, he was the lead person in the development of a point of care lateral flow assay for the sero-diagnosis of Lyme disease and led the effort that resulted in the FDA approval and a CLIA waver for that test. We have experience in preparing assays for the FDA application process. Biopeptides Corp. is developing and licensing technologies for two areas of infectious disease, novel immunodiagnostics assays and mucosal vaccines. The company has obtained 8 SBIR Phase I awards and 3 SBIR phase II awards. Importantly, our NIH funded research has been quite successful and has led to the development of an array of technologies that relate to Lyme disease, including Lyme disease serodiagnosic assays, a Lyme disease IFNgamma release assay, and an oral wildlife vaccine. We have generated multiple patents and patent applications. 

We provide R&D services for labs looking to develop antibody and cellular based diagnostic assays for a variety of diseases, but specializing in tick-transmitted diseases. Please contact us for more information